<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825005</url>
  </required_header>
  <id_info>
    <org_study_id>12-4-008</org_study_id>
    <nct_id>NCT01825005</nct_id>
  </id_info>
  <brief_title>Predicting Outcome in Cervix Carcinoma: a Prospective Study</brief_title>
  <acronym>POCER</acronym>
  <official_title>Predicting Outcome in Cervix Carcinoma: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim is to validate and improve the predictive model for survival and toxicity in
      patients with cervical cancer through multicentric prospective data collection. The data
      contain information on patient, tumor and treatment characteristics. For this study,
      additional health related QOL scores will be assessed using the EORTC Quality of Life
      Questionair-CX24 and C30. The long term aim, beyond this specific study, is to build a
      Decision Support System based on the predictive model validated in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>five-year overall survival rate</measure>
    <time_frame>5 years  after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessment  of the overall survival 5 years after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>three-year distant disease free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessment of distant disease free survival, 3 years after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>three-year local disease free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessment of local disease free survival, 3 year after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>five-year distant disease free survival</measure>
    <time_frame>5  years</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessment of distant disease free survival,5 years after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>five-year local disease free survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessment of local disease free survival, 5 years after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with early adverse events as a measure of safety and tolerability</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with late adverse events as a measure of safety and tolerability</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>group 1:surgery</arm_group_label>
    <description>treatment = surgery only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2: radiotherapy</arm_group_label>
    <description>treatment = radiotherapy only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3: RT and CT, and/or hyperthermia</arm_group_label>
    <description>treatment=  radiotherapy combined with chemotherapy and/or hyperthermia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4: stage IVb , any treatment</arm_group_label>
    <description>cervical cancer stage IV b, treatment =  any systemic or radiation therapy and supportive care</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with cervical cancer can be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological or cytological proven cervical cancer

          -  informed consent according to national rules

        Exclusion Criteria:

          -  no histological or cytological proven cervical cancer

          -  no informed consent according to national rules
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P Lambin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maas tricht University hospital, dep of radiotherapy (Maastro clinic)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>L. Lutgens, MD, PhD</last_name>
    <phone>+31 88 44 55 666</phone>
    <email>ludy.lutgens@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>C. van Gestel, MD</last_name>
    <phone>+ 31 88 44 55 666</phone>
    <email>kitty.vangestel@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L Lutgens, MD, PhD</last_name>
      <phone>+31 88 44 55 666</phone>
      <email>ludy.lutgens@maastro.nl</email>
    </contact>
    <investigator>
      <last_name>P. Lambin, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bloemfontein medicross</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
